News | Heart Valve Technology | October 07, 2016

Northwestern Medicine First in Illinois to Implant New FDA-Approved Aortic Valve

Second in the United States to implant Edwards Intuity Elite valve with newly designed deployment system

Northwestern Medicine, Edwards Lifesciences, Intuity Elite suturless aortic valve, first in Illinois

Edwards Intuity valve image courtesy of Northwestern Medicine

October 7, 2016 — A Northwestern Medicine cardiac surgeon was recently the first in Illinois and second in the United States to implant the Edwards Intuity Elite sutureless aortic valve in a patient with coronary artery disease. The device was implanted through the newly U.S. Food and Drug Administration (FDA)-approved, minimally invasive delivery system.

Patrick McCarthy, M.D., executive director of Northwestern Medicine Bluhm Cardiovascular Institute and chief of cardiac surgery at Northwestern Memorial Hospital, led the team that implanted the aortic valve in Robert Kurinsky, a 74-year-old retiree from Oak Brook, Ill. Kurinsky had been treating his slowly deteriorating heart valve since 2012 primarily through medication.

“Using this newly approved valve system helped replace Mr. Kurinsky’s valve in only 12 minutes, which means less trauma to the body and a quicker recovery time,” said McCarthy, who is also the Heller-Sacks Professor of Medicine at Northwestern University Feinberg School of Medicine. “The valve opening is slightly larger than a standard valve, a positive feature for heart function in the coming years. We are always looking to find the safest and most effective means of treating our patients, and I was pleased we could offer this option to Mr. Kurinsky days after the FDA approved it.”

Traditionally, open-heart surgery is the preferred method for valve replacement but increasingly cardiologists and cardiac surgeons are turning to minimally invasive approaches, a critical sea change in the field of cardiac care. McCarthy led the clinical trial at Northwestern Medicine Feinberg School of Medicine for the new valve prior to its approval by the FDA.

The FDA approved, in August 2016, the advanced Edwards Intuity Elite valve system, a deployment device that incorporates some elements of transcatheter aortic valve replacement (TAVR), a minimally invasive valve replacement system.

Kurinsky said he was thrilled to learn of a less invasive option to replace his aortic valve just days before his scheduled surgery. His wife Carol Kurinsky said she could not believe when he picked up the phone in the intensive care unit and said hello the morning after the surgery. She had left him late the night before and he was on a breathing tube.

“I was told my aortic valve was closing, and we came to Northwestern for a second opinion,” said Kurinsky, who works part-time as a golf starter and is an avid international traveler, two avocations he plans to return to soon. “Coming to Northwestern and Dr. McCarthy was the best decision we made.”

For more information: www.edwards.com

Related Content

The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di